AKERO THERAPEUTICS INC (AKRO) Stock Income Statement
NASDAQ:AKRO - Nasdaq - US00973Y1082 - Common Stock - Currency: USD
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 285.42M | 172.87M | 115.16M | 100.89M | 80.15M | |||
| Research and Development | 247.50M | 141.80M | 85.28M | 81.76M | 64.92M | |||
| Selling, General, and Administrative Expenses | 37.93M | 31.07M | 29.87M | 19.13M | 15.24M | |||
| Operating Income | -285.42M | -172.87M | -115.16M | -100.89M | -80.15M | |||
| Interest Income/Expense | 33.36M | 21.11M | -740.00K | 110.00K | 950.00K | |||
| Other Income/Expense | N/A | N/A | 3.86M | N/A | N/A | |||
| Income Before Taxes | -252.06M | -151.76M | -112.03M | -100.78M | -79.21M | |||
| Income Tax | N/A | N/A | 0.00 | 0.00 | 0.00 | |||
| Net Income | -252.06M | -151.76M | -112.03M | -100.78M | -79.21M | |||
| EBITDA | -285.40M | -172.84M | -115.12M | -100.85M | -80.13M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -3.75 | -2.89 | -2.87 | -2.89 | -2.52 | |||
| Non GAAP EPS | -3.75 | -2.85 | -2.92 | -2.89 | -2.48 | |||
| Statistics | ||||||||
All data in USD